8-K: Supernus Pharmaceuticals to Acquire Sage Therapeutics, Bolstering Neuropsychiatry Portfolio with ZURZUVAE

Supernus Pharmaceuticals, Inc. has entered into a definitive agreement to acquire Sage Therapeutics, Inc. for an upfront cash payment of $8.50 per share plus a contingent value right of up to $3.50 per share, aiming to strengthen its neuropsychiatry product portfolio with ZURZUVAE.

Summary

• Supernus Pharmaceuticals, Inc. (Supernus) has signed a definitive Agreement and Plan of Merger to acquire Sage Therapeutics, Inc. (Sage) through a tender offer.
• The acquisition price is $8.50 per share in cash at closing, totaling approximately $561 million, plus one non-tradable contingent value right (CVR) per share, collectively worth up to $3.50 per share in cash, for a total potential consideration of up to $12.00 per share or approximately $795 million.
• The CVRs are payable upon achieving specific net sales and commercial milestones for ZURZUVAE, Sage's FDA-approved oral medicine for postpartum depression (PPD).
• Supernus will report collaboration revenue representing 50% of total net revenue Biogen, Inc. records for ZURZUVAE in the U.S. through an existing collaboration agreement.
• The transaction is expected to be significantly accretive to Supernus's adjusted operating income, operating income, and EPS in 2026, with potential annual cost synergies of up to $200 million.
• The acquisition will be funded through Supernus's existing balance sheet cash.
• The transaction is anticipated to close in the third quarter of 2025, subject to customary closing conditions, including regulatory approvals and the tender of a majority of Sage's outstanding common stock.

Sentiment

Score: 9

Explanation: The document presents the acquisition as a highly strategic and financially beneficial move for Supernus, emphasizing significant growth, diversification, and synergy potential. The tone is overwhelmingly positive, with risks presented as standard forward-looking statements rather than immediate concerns.

Positives

• Strengthens Supernus's leading presence in neuropsychiatric conditions by adding ZURZUVAE, an innovative commercial product.
• Augments Supernus's growth profile by adding a significant fourth growth product and further diversifies its revenue base and cash flow.
• Expected to be significantly accretive to adjusted operating income, operating income, and EPS in 2026.
• Anticipated cost synergies of up to $200 million on an annual basis due to strong fit with existing Supernus infrastructure.
• Expands Supernus's central nervous system (CNS) discovery platforms and expertise.
• ZURZUVAE is the first and only FDA-approved oral medicine for postpartum depression, providing a novel treatment option.
• The acquisition is funded through existing balance sheet cash, indicating financial strength.

Negatives

• None explicitly stated in the document.

Risks

• The proposed acquisition may not be completed.
• Competing offers or acquisition proposals for Sage may be made.
• There is a risk of delay or failure of the tender offer conditions to be satisfied or waived, including insufficient shares of Sage common stock being tendered.
• Failure or delay in receiving required regulatory approvals for the proposed acquisition.
• Prior to the completion of the transactions, Supernus or Sage's business may experience significant disruptions due to transaction-related uncertainty.
• The announcement and pendency of the transactions may make it more difficult to establish or maintain relationships with employees, manufacturers, suppliers, vendors, business partners, and distribution channels to patients.
• The occurrence of any event, change, or other circumstance could give rise to the termination of the acquisition agreement.
• Stockholder litigation in connection with the proposed transaction may result in significant costs of defense, indemnification, and liability.
• There is a risk that Supernus may not realize the potential benefits of the transactions.
• ZURZUVAE's launch and commercialization efforts in the U.S. for PPD may not be successful.
• ZURZUVAE may not achieve the clinical benefit, clinical use, or market acceptance expected, or may encounter reimbursement, market access, process-related, or other issues, including competition.
• ZURZUVAE may never become the standard of care for women with PPD.
• Risks related to the non-achievement of the CVR milestones, meaning holders of CVRs may not receive any payments in respect of those CVRs.

Future Outlook

Supernus expects the acquisition to accelerate its midto long-term revenue and cash flow growth, further diversifying its revenue base. The company plans to build on ZURZUVAE's U.S. growth momentum and collaboration with Biogen, aiming to expand reach to additional prescribers and establish ZURZUVAE as the first-choice treatment for women with PPD. Supernus will also evaluate the potential of Sage's pipeline programs to sustain innovation and growth in CNS and psychiatry.

Management Comments

• Jack Khattar, President and CEO of Supernus Pharmaceuticals: "This acquisition represents a major step in bolstering our future growth. It augments our growth profile by adding a significant fourth growth product to our portfolio and further diversifies our sources of future growth. ZURZUVAE aligns with our focus of acquiring novel value-enhancing and clinically-differentiated medicines to treat CNS conditions. We have a proven track record of strong commercial execution, and we look forward to building on ZURZUVAE’s U.S. growth momentum and collaboration with Biogen, so that more women with postpartum depression can benefit from this novel treatment."
• Barry Greene, Chief Executive Officer, Sage Therapeutics: "Since our founding, Sage Therapeutics has been committed to pioneering new solutions in brain health, one of the most complex and underserved areas of medicine. We are proud of what we’ve accomplished, including successfully developing and commercializing ZURZUVAE, the first and only oral treatment for women with postpartum depression. This transaction follows a comprehensive strategic review by our Board of Directors, and I am confident this deal maximizes value for shareholders. I want to express my deepest gratitude to the Sage team for their unwavering commitment to brain health and improving the lives of patients. We look forward to our next chapter with Supernus."

Industry Context

The acquisition positions Supernus to strengthen its leading presence in neuropsychiatric conditions by adding ZURZUVAE, the first and only FDA-approved oral medicine for postpartum depression (PPD). PPD is highlighted as a significant and often undertreated condition, affecting approximately 1 in 8 women with a recent live birth. This move allows Supernus to expand its reach into new channels, such as OBGYN prescribers, and leverage its existing relationships with psychiatrists, aligning with its focus on CNS conditions and addressing unmet needs in brain health.

Comparison to Industry Standards

• ZURZUVAE is highlighted as the 'first and only FDA-approved oral medicine indicated for the treatment of postpartum depression in adults,' positioning it uniquely in the market.
• The document does not provide specific comparable companies, projects, or detailed financial results for direct industry benchmarking beyond stating ZURZUVAE's unique market position and its collaboration revenue figures.

Management Changes

Corporate Governance

Legal Proceedings

• Stockholder litigation in connection with the proposed transaction is identified as a risk, which could result in significant costs of defense, indemnification, and liability.

Related Party Transactions

• None disclosed beyond the acquisition agreement itself, which defines the terms of the transaction between Supernus (Parent), Saphire Inc. (Purchaser, a wholly-owned subsidiary of Supernus), and Sage Therapeutics (the Company).

Stakeholder Impact

• **Shareholders (Sage):** Will receive cash and CVRs for their shares, with Sage's Board of Directors unanimously recommending the tender of shares.
• **Shareholders (Supernus):** Expected to benefit from the acquisition being significantly accretive to financial metrics, diversification of revenue, and accelerated growth.
• **Employees (Sage):** Supernus or its affiliates will extend offers of employment to selected employees. Non-continuing employees will receive severance benefits, and transition employees may receive transition payments. The WARN Act notice will be provided to employees.
• **Customers/Patients:** The acquisition aims to expand the reach of ZURZUVAE, potentially benefiting more women with postpartum depression by making the novel treatment more widely available.
• **Biogen, Inc.:** The existing collaboration agreement for ZURZUVAE in the U.S. will continue, with Supernus reporting 50% of net revenue recorded by Biogen.

Next Steps

• Supernus will commence a tender offer for all outstanding shares of Sage Therapeutics, Inc. no later than July 2, 2025.
• Sage will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC.
• The transaction is expected to close in the third quarter of 2025, subject to customary closing conditions and regulatory approvals.
• Following the successful tender offer, Supernus will acquire any untendered Sage shares through a second-step merger.
• Supernus will provide revised full-year 2025 financial guidance after the closing of the transaction.
• Supernus and Sage will work closely on transition and integration planning to ensure continued success.
• Supernus will continue to build on ZURZUVAE's U.S. growth momentum and collaboration with Biogen.
• Supernus will evaluate the potential of Sage's pipeline programs and assess development strategy.

Key Dates

Keywords

Supernus Pharmaceuticals, Sage Therapeutics, Acquisition, Merger, ZURZUVAE, Postpartum Depression, PPD, Neuropsychiatry, CNS, Contingent Value Right, CVR, Biogen, Pharmaceuticals, Biotechnology, Healthcare